VESALIUS-CV: Evolocumab Prevents Cardiovascular Disease in High-Risk DiabetesByMarc P. Bonaca, MD, MPHAugust 7th 2026
500,000 Patients With Diabetes May Lose Healthcare Under New Medicaid LegislationByRyan LivingstonAugust 6th 2026
Retatrutide Cuts Weight, Cardiovascular Disease Risk in TRIUMPH-3ByDiana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Natalie Bellini, DNP, FNP, BC-ADM, CDCESAugust 6th 2026
TRIUMPH-2: Retatrutide Reduces Weight, A1C in Patients With ObesityByDiana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Natalie Bellini, DNP, FNP, BC-ADM, CDCESAugust 5th 2026
Diabetes Dialogue: Retatrutide Phase 3 Data Show Major Weight LossByDiana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Natalie Bellini, DNP, FNP, BC-ADM, CDCESAugust 4th 2026